{
    "2019-05-13": [
        [
            {
                "time": "2023-10-18",
                "original_text": "Lilly's CYRAMZAÂ® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma",
                "features": {
                    "keywords": [
                        "CYRAMZA",
                        "FDA-Approved",
                        "Biomarker-Driven",
                        "Hepatocellular Carcinoma",
                        "ramucirumab"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}